EHA 2026 | Gilteritinib vs Midostaurin FLT3 AML Clinical Outcome Analysis Report

Abstract: EHA-7247 Short: LB5005 The PASHA trial is the first randomized Phase 3 head-to-head comparison of a second-generation FLT3 inhibitor (gilteritinib) against the established first-generation standard (midostaurin), both combined with intensive induction/consolidation chemotherapy and followed by one-year maintenance, in patients with newly diagnosed FLT3-mutated AML eligible for intensive therapy. Results were presented as a Late-Breaking Abstract at EHA 2026 (Stockholm, June 2026) by Dr. Marc Raaijmakers on behalf of the HOVON-AMLSG consortium.